Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients

1990 ◽  
Vol 15 (3) ◽  
pp. 175-184 ◽  
Author(s):  
Daniel R. Ciocca ◽  
Libertad A. Puy ◽  
Liliana C. Fasoli ◽  
Olga Tello ◽  
Juan C. Aznar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Cancer Patients ◽  
Growth Hormone Releasing Hormone ◽  
Corticotropin Releasing Hormone ◽  
Breast Cancer Patients ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone

Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH)

2012 ◽  
Vol 9 (1) ◽  
Author(s):  
Stefan Buchholz ◽  
Stephan Seitz ◽  
Jörg B. Engel ◽  
Alberto Montero ◽  
Olaf Ortmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Experimental Studies ◽  
Growth Hormone Releasing Hormone ◽  
Breast Cancers ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone

AbstractTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is clinically negative for the expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2). Patients with TNBC have a worse clinical outcome, as measured by time to metastasis and median overall survival. Chemotherapy has been the mainstay of treatment of TNBC but responses are disappointing. A substantial proportion of TNBC expresses luteinizing hormone-releasing hormone (LHRH), receptors for LHRH, in addition to receptors for growth hormone-releasing hormone (GHRH). These receptors represent potential therapeutic targets. Potent antagonists of GHRH and LHRH receptors have been developed in recent years and these antagonists inhibit the growth, tumorigenicity and metastatic potential of various human experimental malignancies. These antagonists could be utilized for the treatment of TNBC. The targeted cytotoxic analog of LHRH, AN-152 (AEZS-108) containing doxorubicin, must also be strongly considered for therapy of TNBC. Experimental studies suggest the merit of clinical trials with LHRH antagonists and AEZS-108 in TNBC patients.

Sign in / Sign up

Export Citation Format

Share Document